Editorial

Suzetrigine: First in a New Class of Nonopioid Analgesics for Acute Pain

  • Rathmell, James P. M.D.1
  • Clark, J. David M.D., Ph.D.2
  • Eisenach, James C. M.D.3

  • 1

    Harvard Medical School and the Department of Anesthesiology, Mass General Brigham, Boston, Massachusetts.

  • 2

    Department of Anesthesiology, Perioperative and Pain Medicine, Stanford Medicine, Palo Alto, California.

  • 3

    Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.

Accepted for publication March 19, 2025.

This editorial accompanies the article on p. 1085.

Address correspondence to Dr. Rathmell: [email protected]
Anesthesiology 142(6):p 989-991, June 2025. | DOI: 10.1097/ALN.0000000000005465

Corresponding Article

Suzetrigine, a Nonopioid NaV1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials

  • Bertoch, Todd M.D.1
  • D’Aunno, Dominick M.D.2
  • McCoun, Jessica M.D.3
  • Solanki, Daneshvari M.D.4
  • Taber, Louise M.D.5
  • Urban, Joshua M.D.6
  • Oswald, Jessica M.D., M.P.H.7
  • Swisher, Matthew W. M.D.8
  • Tian, Simon M.D.9
  • Miao, Xiaopeng Ph.D.10
  • Correll, Darin J. M.D.11
  • Negulescu, Paul Ph.D.12
  • Bozic, Carmen M.D.13
  • Weiner, Scott G. M.D., M.P.H.14
Anesthesiology 142(6):p 1085-1099, June 2025. | DOI: 10.1097/ALN.0000000000005460
Copyright © 2025 American Society of Anesthesiologists. All Rights Reserved.
View full text|Download PDF